Tissue Price Rollback, New AI Data Source, Biospecimen Guides & More

Klicken Sie hier, um Fiercebiotech.com zu abonnieren

Laden...

Vor 13 Tagen

Html
Text

This week's Fierce Biotech is brought to you by BioIVT.
Trouble viewing? Click here.

Unlocking New Sources of Biomedical Big Data The quality of data utilized in AI applications greatly impacts the accuracy of the research. BioIVT is launching a new system to access their vast repository of meticulously collected, quality biospecimen data spanning numerous therapeutic areas. Ready to Peek Behind the Curtain?

Biomarker Discovery & Preclinical Development in Neurological Diseases BioIVT is hosting a free symposium on June 25th in San Francisco on breakthroughs and innovations in neurological disease research. Learn More & Register

Roll Back to 2015 Pricing on ASTERAND® Tissue BioIVT has reduced pricing on its ASTERAND® line of disease-state tissue samples to 2015 levels, making high-quality, ethically sourced biospecimens more accessible to researchers. View Options

Researchers' Guide to Products for ADME-Tox Testing Obtaining useful research results is dependent on finding the right test system. This ebook provides an overview of ADME-Tox test systems including advantages and limitations of each; recommendations for different studies; tips on thawing, culturing, plating, and testing; and more. Download Now

Critical Considerations for the Use of Human Biological Specimens Read about potential impacts to research accuracy and funding, how to avoid common pitfalls, and achieving ethical and regulatory compliance in this important blog post. Read More

New Standard Biospecimen Volumes for Faster, Easier Ordering BioIVT has added standard sizes for human and animal blood products like plasma and serum to the standard products on their eCommerce website. This allows for favorable pricing and streamlined ordering through the portal. View Biospecimens

The Power of Disease-State Cells and Diversity in CGT R&D Understanding gender bias and utilizing representative diversity in donor pools is critical for lupus and autoimmune disease research. Using disease-state raw cellular starting materials also offers a unique opportunity to advance effective CGTs. Read More

Subscribe to Receive Future News and Resources from BioIVT Select which types of content you would be interested in, including webinars and other event presentations, publications, news and more. Register Now

Follow BioIVT on social media:

Want to reach 137,000+ Fierce Biotech subscribers with your own message?
Contact [email protected] or call 202-824-5074.

You are currently subscribed as [email protected].
If you no longer wish to receive communications from Fierce Biotech's trusted partners, simply click here to unsubscribe.
Refer to our Privacy Policy.

Questex, LLC
1111B S Governors Ave STE 25792, Dover, DE 19904

Teilen auf

Laden...

Weitere Newsletter von Fiercebiotech.com

| 06.25.25 | New ACIP leader vows 'evidence-based' approach; Bayer's cell therapy unit stops work in immunology, cardiology Fiercebiotech.com
Vor 13 Stunden
Break the Chain: Fix Specialty Medication Roadblocks Fiercebiotech.com
Vor 16 Stunden
Is AI Defining Your Pharma Brand? See How You Rank Fiercebiotech.com
Vor 16 Stunden

Weitere Newsletter von Fiercebiotech.com

Laden...

Tissue Price Rollback, New AI Data Source, Biospecimen Guides & More

Teilen auf

Weitere Newsletter von Fiercebiotech.com

Verwandte Newsletter